作者:Rijpkema, Koen J.、Schuller, Marion、van der Veer, Miriam S.、Rieken, Sjoerd、Chang, Diego L. R.、Balić, Pascal、Todorov, Alex、Minnee, Hugo、Wijngaarden, Sven、Matos, Isaac A.、Hoch, Nicolas C.、Codée, Jeroen D. C.、Ahel, Ivan、Filippov, Dmitri V.
DOI:10.1021/acs.orglett.4c01792
日期:——
crucial for a proper immune response. Accordingly, viruses have evolved ADP-ribosyl hydrolases to remove these modifications, a prominent example being the SARS-CoV-2 NSP3 macrodomain, “Mac1”. Consequently, inhibitors are developed by testing large libraries of small molecule candidates, with considerable success. However, a relatively underexplored angle in design pertains to the synthesis of structural
蛋白质二磷酸腺苷 (ADP) 核糖基化对于正确的免疫反应至关重要。因此,病毒进化出了 ADP-核糖基水解酶来消除这些修饰,一个突出的例子是 SARS-CoV-2 NSP3 宏结构域“Mac1”。因此,通过测试大的小分子候选物库来开发抑制剂,并取得了相当大的成功。然而,设计中相对未充分探索的角度涉及结构基质模拟物的合成。在这里,我们介绍了作为 SARS-CoV-2 NSP3 Mac1 抑制剂的新型腺苷二磷酸核糖 (ADPr) 类似物的合成和生物物理活性。